Table 2 HI antibody response against the three 2011-2012 influenza vaccine antigens 1 and 6 months after IM-MF59 or ID vaccination
Vaccine component | Group (N) | Seroprotection rate (%) | GMT | MFI | Seroconversion rate (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
[95% C.I.] | [95% C.I.] | [95% C.I.] | [95% C.I.] | ||||||||
Pre-vacc. | 1 month | 6 months | Pre-vacc. | 1 month | 6 months | 1 month | 6 months | 1 month | 6 months | ||
A/Perth/16/09 (H3N2) | IM-MF59 | 50.0 | 87.5** | 66.5 | 25.5 | 83.7** | 53.8* | 3.3 | 2.1 | 47.5 | 17.5 |
(40) | [37.3-62.6] | [76.4-93.8] | [52.0-76.1] | [16.3-40.1] | [44.8-156.2] | [27.3-106.2] | [1.9-5.7] | [1.1-4.1] | [35.1-60.2] | [9.8-29.4] | |
ID | 50.0 | 92.5** | 67.5 | 28.3 | 131.3** | 69.1 | 4.6 | 2.4 | 60.0 | 30.0 | |
(40) | [37.3-62.6] | [82.6-97.0] | [54.5-78.2] | [14.7-54.5] | [72.3-238.5] | [33.2-144.0] | [2.8-7.8] | [1.3-4.4] | [47.0-71.7] | [19.6-42.9] | |
A/California/7/09 (H1N1) | IM-MF59 | 25.0 | 72.5** | 40.0 | 15.0 | 55.0** | 22.0 | 3.7 | 1.5 | 50.0 | 7.5 |
(40) | [15.5-37.6] | [59.7-82.4] | [28.3-53.0] | [9.2-24.5] | [31.9-94.8] | [13.0-37.3] | [2.4-5.6] | [1.1-2.0] | [37.3-62.6] | [3.0-17.4] | |
ID | 32.5 | 70.0** | 50.0 | 15.8 | 61.0** | 29.7 | 3.8 | 1.9 | 42.5 | 17.5 | |
(40) | [21.7-45.5] | [57.1-80.3] | [37.3-62.6] | [9.0-28.0] | [31.4-118.4] | [17.0-52.5] | [2.2-6.8] | [1.2-2.8] | [30.5-55.5] | [9.8-29.4] | |
B/Brisbane/60/08 | IM-MF59 | 55.0 | 75.0 | 57.5 | 31.5 | 50.8 | 31.5 | 1.6 | 1.0 | 10.0 | 0.0 |
(40) | [42.1-67.2] | [62.4-84.4] | [44.5 -69.5] | [18.8–52.7] | [29.6-87.0] | [18.5-53.5] | [1.3-2.0] | [0.9-1.1] | [4.6-20.5] | [0.0-6.3] | |
ID | 40.0 | 75.0 | 60.0 | 20.0 | 62.9* | 35.9 | 3.2 | 1.8 | 40.0 $$ | 17.5 $$ | |
(40) | [28.3-53.0] | [62.4-84.4] | [47.0-71.7] | [12.7-32.0] | [35.6-114.7] | [20.7-62.2] | [1.7-6.0] | [1.0-3.1] | [28.3-53.0] | [9.8-29.4] | |